Study of olorofim for progressive coccidioidomycosis
Part of Infections clinical trials.
This trial tests if adding the drug olorofim to standard care can help people with a serious fungal infection called coccidioidomycosis that has spread beyond the lungs and is not getting better with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and weigh at least 88 pounds (40 kg).
- You must have coccidioidomycosis that has spread to other parts of the body and is getting worse or not responding to treatment.
- You must have already tried two different antifungal drugs from the triazole family (with or without amphotericin B).
- You cannot have fungal infection limited to lung cavities only.
- You cannot be pregnant or breastfeeding.
- You cannot have a history of allergic reaction to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why “Valley fever” is difficult to treat or has spread beyond the lungs, and how a person’s genetics may be involved. You may be asked for blood or other samples for genetic testing and for storing samples for future research.
This trial tests a new drug called olorofim for people recently diagnosed with coccidioidomycosis (Valley fever) meningitis, a serious fungal infection of the brain lining. It aims to see if the drug is safe and effective as an early treatment.
This trial tests different combinations of medicines for people hospitalized with a serious fungal infection called histoplasmosis. The goal is to find the most effective way to treat the infection and help patients recover faster.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
Hear when a new Coccidioidomycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.